SCHEMBL19743547

SCHEMBL19743547

CC1(C)OB(c2cccc(C(N)=O)c2F)OC1(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F11 P03951 3/20 0.37
F2 P00734 2/20 0.37
PRSS1 P07477 2/20 0.37
PRSS2 P07478 2/20 0.37
PRSS3 P35030 2/20 0.37
JAK2 O60674 2/20 0.36
BTK Q06187 2/20 0.36
OPRM1 P35372 1/20 0.35
LIPG Q9Y5X9 2/20 0.35
LPL P06858 1/20 0.35
ROCK2 O75116 1/20 0.34
PARP1 P09874 5/20 0.33
CXCR2 P25025 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LIPE Q05469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3185687 0.86 ALB (0.39) F11F2PRSS1PRSS2PRSS3
SCHEMBL3076866 0.84 ALDH1A1 (0.41) F11F2PRSS1PRSS2PRSS3
SCHEMBL31023154 0.84 ALDH1A1 (0.41) F11F2PRSS1PRSS2PRSS3
SCHEMBL2029210 0.83 JAK2 (0.39) F11F2PRSS1PRSS2PRSS3
SCHEMBL21805777 0.82 MEN1 (0.36) JAK2BTKLIPGLPLCXCR2
SCHEMBL29627829 0.82 SLC6A4 (0.39) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL17939979 0.82 SLC6A4 (0.39) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL24630498 0.80 LPL (0.46) JAK2BTKLIPGLPL
SCHEMBL12215759 0.79 TSHR (0.47) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL29469138 0.79 F11 (0.37) F11F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 US disclosed
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 EP disclosed
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-04-06 US disclosed
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-05-06 US disclosed
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-02-16 US disclosed
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-04-23 US disclosed
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-02-18 US disclosed
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-07-04 US disclosed
EP-3472165-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2019-04-24 EP disclosed
WO-2017220477-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 F11 4758/4885F2 4867/4885PRSS1 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.